Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study

Current Medical Research and Opinion

Volumn 30, Issue 7, 2014, Pages 1219-1230

  Seino, Yutaka ^a   Sasaki, Takashi ^b   Fukatsu, Atsushi ^c   Sakai, Soichi ^d   Samukawa, Yoshishige ^d  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Yachiyo Hospital   (Japan)

^d TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Japanese; Luseogliflozin; Monotherapy; Phase II clinical study; Placebo; Sodium glucose cotransporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARBOHYDRATE; CORTICOSTEROID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE BODY; LUSEOGLIFLOZIN; ORAL ANTIDIABETIC AGENT; PLACEBO; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SORBITOL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FASTING PLASMA GLUCOSE; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEAL TOLERANCE TEST; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTITIS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; POSTPRANDIAL PLASMA GLUCOSE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; ETHNOLOGY; JAPAN; METABOLISM; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; SORBITOL; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84902245089     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.901943     Document Type: Article

References (27)

1. International Diabetes Federation. IDF Diabetes Atlas 5th Edition 2012 Update: New Estimates for 2012 of Diabetes Prevalence, Mortality, and Healthcare Expenditure. 2012
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
3. Ahren B. DPP-4 inhibition and islet function. J Diabetes Investig 2012;3:3-10
4. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
5. Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig 2012;3:503-9
6. Kubota A, Yabe D, Kanamori A, et al. Factors influencing durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig 2014: Published online 11 February 2014, doi:10.1111/jdi.12182
7. Sabolic I, Vrhovac I, Eror DB, et al. Expression of Na-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 2012;302:C1174-88
8. Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig 2012;3:352-3
9. Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
10. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60:890-8
11. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22:104-12
12. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304:F156-67
13. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-90
14. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
15. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
16. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502
17. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-Anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-Thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53:3247-61
18. Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011;164:181-91
19. Sasaki T, Seino Y, Fukatsu A, et al. Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial. Adv Ther 2014: Published online 18 February 2014, doi:10.1007/s12325-014-0102-3
20. Sasaki T, Seino Y, Fukatsu A, et al. TS-071, a novel potent and highly selective renal sodium-glucose co-Transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th European Association for the Study of Diabetes (EASD) Annual Meeting, 12-16 September 2011. Lisbon, Portugal, 2011
21. Fujimoto WY, Boyko EJ, Hayashi T, et al. Risk factors for type 2 diabetes: Lessons learned from Japanese Americans in Seattle. J Diabetes Investig 2012;3:212-24
22. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 2002;55:65-85 (Pubitemid 34036538
23. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012;3:8-10
24. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
25. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-204
26. Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-Transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28:1167-71
27. Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-Transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-8.